3 stories mentioning VORUpdated 54m ago
Every FINWIRES story that references VOR, newest first.
Vor Biopharma (VOR) has an average rating of buy and mean price target of $37.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $23.20, Change: $-0.18, Percent Change: -0.75%
Vor Biopharma (VOR) shares were down 1.2% in Tuesday trading after the company reported its Q2 results.The company reported a Q2 net loss of $1.16 per diluted share, narrower than a loss of $251.24 a year earlier.Analysts polled by FactSet expected a loss $0.70.As of June 30, the company said it had $466.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations through early 2029 taking into account $48.4 million net proceeds from at-the-market sales during July.Price: $23.13, Change: $-0.24, Percent Change: -1.03%
Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss
